The Global Burden of Chronic Kidney Disease: How Valid Are the Estimates?

Richard J. Glassock, Christopher Winearls

Abstract

Background/Aims: The values for the global prevalence of chronic kidney disease (CKD) are poorly understood. Current classification schemas may overstate the prevalence of CKD. This minireview analyzes the pitfalls in the use of current classification approaches for identifying CKD on a global basis. Methods: Literature review and comment. Results: Published estimates for the global burden of CKD are likely to be incorrect and inflated. Over estimations of prevalence have occurred due to flaws in the classification systems employed and in ascertaining methods. Conclusions: A revision of the current system of diagnosing and classifying CKD is needed in order to determine with greater precision true global burden of CKD. A new system is proposed.

Key Words
Chronic renal disease • End-stage kidney disease • Epidemiology • Glomerular filtration rate

Introduction

Chronic kidney disease (CKD) has a worldwide distribution. Great concern has been repeatedly expressed that CKD is threatening to reach epidemic proportions thus creating the potential to overwhelm the limited resources of less 'robust' economies [1]. This review is intended to dispassionately examine the global prevalence of CKD in order to better understand its roots as well as to outline new approaches for accurately quantifying the true global burden of CKD.

The story really begins in 2002 when a novel definition, classification and staging system of CKD was promulgated by the National Kidney Foundation (NKF) and the Kidney Disease Outcome Quality Initiative (KDOQI) [2]. Although this construct had not been tested in the field, it was soon adopted as a reference tool for a large number of epidemiological studies throughout the world. Long before KDOQI-CKD, many countries had already established registries to assemble epidemiologic data on the incidence (or more correctly, acceptance rates) and prevalence of treated end-stage renal disease (ESRD). The United States Renal Data System (USRDS) is a preeminent example of this effort [3]. Secular variation in the size of this easily defined ESRD cohort are a direct consequence of a composite of: (i) the actual incidence and prevalence of underlying CKD and its progression to ESRD; (ii) survival from competing causes of mortality prior to the need for renal replacement therapy (RRT); (iii) the acceptance into a RRT program (dialysis and/or transplantation) according to local standards of practice and availability of care; (iv) the overall improvement in patient survival after initiation of RRT. A clear need emerged for the assessment of the overall burden of CKD, prior to RRT, in the community at large. Such an assessment would give insights into the changing pool from which patients destined to develop ESRD must arise. Defining treated ESRD is simple, accurate and straightforward; defining CKD prior to RRT is not. The approach taken by KDOQI was to use multiple and absolute thresh-
old criteria for defining the stages of CKD [2] (table 1); including an estimate of glomerular filtration rate (eGFR); evidence of ‘renal damage’ (such as abnormal protein excretion or urinary sediment); structural abnormalities (detected by imaging or renal histology), and including a time dimension (persistence for \( \geq 3 \) months) to assure true ‘chronicity’. The KDOQI construct became the preferred method for epidemiological studies of the CKD burden throughout the world. It was adopted, with only minor modifications by the Kidney Disease Improving Global Outcomes (KDIGO) organization, in 2007 [4].

However, since its introduction, concerns have steadily emerged over the validity of the KDOQI-CKD classification system in identifying ‘true’ CKD (a disease being an abnormal state which directly or indirectly confers some measurable disadvantage upon an individual compared to a normal one without a disease). These concerns have been cogently expressed, but have not yet yielded any appreciable response in terms of altering the classification schema [5–7]. Questions have also arisen as to how ‘transportable’ the KDOQI-CKD system is to countries other than the USA, its country of origin.

### How Accurate Is the KDOQI Classification in Identifying CKD?

The KDOQI-CKD classification system comprises five stages (table 1) [2]. CKD stages 1 and 2 require some evidence of ‘kidney damage’ such as albuminuria (postulated as any magnitude above a ‘normal threshold’). CKD stages 1 and 2 are separated from each other based on differences in eGFR, as quantified by an estimating formula, such as the Modification of Diet in Renal Disease (MDRD) four-variable equation using a serum creatinine level and face area.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>eGFR(^a) ml/min/1.73 m(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>kidney damage(^b)</td>
<td>( \geq 90 )</td>
</tr>
<tr>
<td>2</td>
<td>kidney damage(^b)</td>
<td>60–89</td>
</tr>
<tr>
<td>3</td>
<td>–</td>
<td>30–59</td>
</tr>
<tr>
<td>4</td>
<td>–</td>
<td>15–29</td>
</tr>
<tr>
<td>5</td>
<td>–</td>
<td>(&lt; 15 ) or on dialysis</td>
</tr>
</tbody>
</table>

\( a \) eGFR = estimated glomerular filtration rate. The Modification of Diet in Renal Disease (MDRD) four-variable formula is recommended for estimating GFR [for details, see 2].

\( b \) Kidney damage = proteinuria (micro- or macroalbuminuria), hematuria, abnormal composition of blood or urine, abnormal imaging, or abnormal renal biopsy. The qualifying kidney damage and/or eGFR values must persist for \( \geq 3 \) months.

When the eGFR values were \( > 60 \) ml/min/1.73 m\(^2\) [11]. Thus, the separation into stage 1 and 2 CKD based on eGFR values of between 60 and 89 ml/min/1.73 m\(^2\) (stage 2) and \( \geq 90 \) ml/min/1.73 m\(^2\) (stage 1) becomes spurious if one uses the MDRD equation for such stratification. In addition, an eGFR of \(< 90 \) but \( > 60 \) ml/min/1.73 m\(^2\) is described as ‘mildly reduced’, implying that these values are abnormal despite the fact that only a minority of the population at large actually have an eGFR of \( > 90 \) ml/min/1.73 m\(^2\). The inclusion of microalbuminuria as meeting the definition of ‘kidney damage’ in stage 1 or 2 CKD is even more problematical. It is likely that a patient with an established diagnosis of diabetes mellitus (type 1 or type 2) will have an early form of ‘incipient’ diabetes-related kidney damage if their urinary albumin excretion is raised irrespective of the GFR [12]. But can we say, with a similar level of confidence, that a non-diabetic individual with a similar raised urinary albumin excretion and ‘normal’ eGFR also has ‘kidney damage’? Such albuminuria is commonly found in obese persons, in the presence of systemic chronic inflammation or cancer, and may also be found in apparently healthy elderly individuals [13]. Such states might represent a generalized form of vascular endothelial dysfunction somehow resulting in an abnormal rate of albumin excretion in the urine but is it necessary to label them as suffering from ‘kidney damage’ or a disease? A risk factor is not a disease. Uncertainty persists as to the mechanisms underlying such abnormal urinary albumin excretion: specifically, is it due to abnormal transglomerular passage of albumin or inefficient reabsorption or reclamation of normally filtered...
albumin, or both [14, 15]? Many studies have convincingly shown that a rise in albumin excretion rate, above normal but not to levels easily detected by conventional semiquantitative methods ('dipstick positive' proteinuria) is associated with an increased risk of cardiovascular events, including perhaps the development of hypertension [16, 17]. But not all studies are in agreement [18] and it is unclear whether such 'microalbuminuria' is a marker of 'kidney' disease or 'generalized vascular' disease [19]. What is clear is that designating low levels of albumin excretion alone as diagnostic of CKD will greatly inflate the numbers of subjects labeled as having CKD stage 1 or 2.

Unlike CKD stage 1 and 2, the KDOQI definition of CKD stages 3–5 does not require any corroborating evidence of 'kidney damage'. It is presumed that any eGFR <60 ml/min/1.73 m² is 'prima facie' evidence for the presence of kidney disease [2]. Such an arbitrary definition of CKD, using an absolute threshold of eGFR, places many subjects in this category even though they have no other corroborating features of kidney disease. This is particularly true for those categorized as stage 3 CKD (30–59 ml/min/1.73 m²). Thus, an eGFR value of <60 ml/min/1.73 m² becomes a de facto threshold for the diagnosis of CKD although this estimate has no such precision [5–7].

The values for eGFR decline normally with age and tend to be lower in females than in males [20, 21] (fig. 1a, b). The threshold of <60 ml/min/1.73 m² for defining stages 3–5 CKD ‘captures’ a large number of older subjects (>65 years of age) who are otherwise healthy and free of any evidence of ‘kidney disease’, such as hypertension, diabetes or overt albuminuria, and labels them as having an intermediate stage (3 of 5) of a potentially lethal or life-altering chronic disease. Any subject with an eGFR of <30 ml/min/1.73 m² (CKD stages 4 and 5) must surely have significant kidney disease with very rare exceptions (such as severe congestive heart failure with a functional decline in eGFR), irrespective of age, concomitant imaging or urinary findings.

The MDRD method of estimating eGFR was developed from measurements in subjects with well-defined kidney disease and among a heterogeneous population of adults in the USA. It is appropriate to question whether this equation can be applied in an unmodified form to other circumstances, including those with marked differences in lean body mass, habitual protein intake, or geographic ancestry compared to the population from which the equation was derived. Several studies have already shown that the MDRD equation needs modification to meet the circumstances which prevail in a variety of conditions.
of populations [5, 22, 23]. The obligate standardization of calculated eGFR to a ‘normal’ BSA of 1.73 m² in the MDRD approach also gives rise to some informative anomalies with clinical significance [24]. To illustrate this point, two individuals of identical age, sex, ancestry, serum creatinine concentration and body mass index (kg/m²) but with greatly different calculated body surface area will have the same calculated MDRD eGFR but will have greatly different absolute (uncorrected GFR). The absolute (uncorrected) eGFR is higher in the larger as compared to the smaller subject. Which of the two values for the larger individual is the correct one for determining the presence or absence of CKD?

The legitimacy of the use of eGFR as a method for diagnosing CKD has not been uniformly accepted. For example, recent studies have suggested that the MDRD calculated eGFR was no better than serum creatinine concentration alone in ‘diagnosing’ CKD, using the current KDOQI criteria [25, 26]. The necessity for repeated measurement to confirm the ‘chronicity’ of the decline in eGFR or the persistence of the manifestations of kidney damage imposes a severe limitation upon cross-sectional epidemiological studies. The lack of confirming studies may give rise to many ‘false positives’, inflating estimates of the prevalence of CKD.

In summary, the KDOQI formulation for diagnosing and stratifying CKD is seriously flawed and its use in the definition of the prevalence of CKD in epidemiologic studies is very likely to yield a marked overestimate of the prevalence of true and relevant CKD in the community at large. These overestimates will most likely be evident in the elderly, especially females, and among otherwise healthy adults with underlying acute or chronic inflammation or with generalized vascular disease. In this latter group, the concept of the presence of a kidney disease is blurred, since many will have some morphological evidence of kidney injury, but only as a part of a more generalized vascular pathology. A further question should be raised regarding the appropriateness of including small increases in urinary albumin excretion to define CKD in the absence of diabetes, hypertension or obesity.

**Can the KDOQI Criteria Be Used to Determine the Global Prevalence of CKD?**

The use of the MDRD eGFR formula in populations having characteristics different from those originally used to derive the formula can lead to errors in classification. It seems obvious that the application of the KDOQI criteria will require a population-specific derivation of the estimating equation. This has already been found to be true for both Chinese subjects living in Beijing, and for Japanese subjects [5, 22, 23]. Replacement of serum creatinine with cystatin C-based estimations of GFR, or the use of both values simultaneously may avoid some of these problems but this is not yet proven [27]. Standardization of eGFR for body surface area may not be appropriate for all populations and can introduce its own errors [24]. The prevailing and habitual dietary protein intake influenced by cultural and socioeconomic differences can also have profound effects on measured GFR as well as its estimation by serum creatinine-based formulas [28]. Concomitant malnutrition or chronic inflammation, so prevalent in many developing countries, will also likely have an effect on the parameters used in the KDOQI formulation to define ‘chronic kidney disease’. Thus, the eGFR ‘threshold’ needed for defining ‘true’ CKD in the absence of any signs of ‘kidney damage’ is very likely to differ from population group to population group.

It is also obvious that estimation of the true burden of CKD in any particular region of the world cannot reliably be made by examining either a random sample of hospitalized patients, subjects who ‘volunteer’ for organized screening clinics or who are receiving regular ambulatory care under medical supervision [29]. These samples would be too biased to be considered representative of the population as a whole. For accurate estimation of the true community-based burden of CKD, a random and representative sample of the general population needs to be examined. The National Health and Nutrition Examination Surveys (NHANES) conducted periodically in the USA are about as representative of ‘population-wide’ surveys as can be practically executed [30]. These surveys, mostly based on single measurements of serum creatinine concentration and urinary albumin excretion, have indicated a prevalence of KDOQI-CKD stages 1–4 of about 13.07% of adults (>20 years of age) in the non-institutionalized population in the USA during the period of 1999–2004 (stage 1 = 1.78%, stage 2 = 3.24%, stage 3 = 7.69%, stage 4 = 0.35%) [30]. These percentages translate into 26.3 million individuals with stage 1–4 CKD in the USA – about 55 times the number patients with treated ESRD in the USA as of December 31, 2005. Stage 3 CKD accounted for about 60% of the total number of subjects and 52% of these were over 60 years of age, predominantly females. Of those with stage 3 CKD, 76% had no abnormal proteinuria and ‘dipstick’ detectable proteinuria was detected in only 6%. Of those defined as having stage 1 or
2 CKD (with an eGFR >60 ml/min/1.73 m²), only 11% had ‘macroalbuminuria’ and 89% had ‘microalbuminuria’. Thus, the great majority of subjects with KDOQI-defined stage 3 CKD will be older than 60 years of age, and have no abnormal proteinuria; whereas those with KDOQI-defined stage 1 and 2 CKD will most often be younger than 65 years of age and have predominantly microalbuminuria. Patients with KDOQI stage 4 CKD (eGFR 15–29 ml/min/1.73 m²) are far less prevalent than all of the other stages of CKD (accounting for <3% of the total KDOQI CKD stages 1–4) [30]. Subjects with stage 4 CKD are also mostly over 60 years of age and 66% have abnormal proteinuria. Globally, approximately 12–16% of the population is over age 60 years, so the estimates of global CKD burden need to be adjusted for the age profile of the population under study. Use of the KDOQI formula for estimating CKD prevalence in populations having a higher proportion of older individuals will pari passu lead to a higher prevalence of KDOQI-defined CKD; CKD prevalence, as defined by KDOQI, will track with the eGFR values for the population as a whole.

Is it appropriate to label older (otherwise healthy) individuals with eGFR values that are within the 95% confidence intervals for age and gender as having CKD in the absence of other manifestation of ‘kidney damage’? We think not. Labeling individuals with ‘normal’ eGFR (≥60 ml/min/1.73 m²) and only isolated ‘microalbuminuria’ without diabetes, hypertension or obesity of having CKD may also be inappropriate. If these subjects were also excluded, the overall prevalence of ‘CKD’ would likely be less than 5% of the population. The extent of the ‘false positive’ error rates introduced by the lack of confirming values of eGFR in epidemiological studies is not known with precision, but they have been as high as 30% in some studies [31]. If all of these ‘adjustments’ were taken into account, the prevalence of CKD would decline to about 3.5 from 13.07% or to 7.04 from 26.3 million; a reduction in prevalence counts of CKD equivalent to about 19,300,000 persons in the USA alone.

Studies of the prevalence of CKD carried out in population-wide surveys other than the USA have provided varied results [20–23, 32–42] (table 2). Most of these studies have applied the KDOQI-CKD classifications without any modifications, while a few have attempted to develop new eGFR estimating equations more appropriate for the population characteristics [22, 23]. These studies have generated an estimated total population burden of KDOQI-defined stages 1–4 CKD of about 13.2% (unweighted average of all studies; range 10.3–16.3% (table 2)), which is surprisingly close to that estimated for

---

**Table 2.** Estimation of population-wide prevalence of KDOQI-defined stage 1–4 CKD in selected countries

<table>
<thead>
<tr>
<th>Country, study, year</th>
<th>CKD prevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>stage 1</td>
</tr>
<tr>
<td>USA (NHANES, 1999–2004)</td>
<td>1.8</td>
</tr>
<tr>
<td>China (Beijing, 2008)</td>
<td>7.4</td>
</tr>
<tr>
<td>China (Inter-Asia, 2005)</td>
<td>na</td>
</tr>
<tr>
<td>Norway (HUNT-II, 1999)</td>
<td>2.7</td>
</tr>
<tr>
<td>Australia (AusDiab, 2003)</td>
<td>5.1</td>
</tr>
<tr>
<td>Spain (EPIRCE, 2005)</td>
<td>7.6</td>
</tr>
<tr>
<td>Spain (Hortega, 2004)</td>
<td>na</td>
</tr>
<tr>
<td>Japan (7 prefectures, 2007)</td>
<td>na</td>
</tr>
<tr>
<td>Thailand (InterAsia, 2005)</td>
<td>na</td>
</tr>
<tr>
<td>United Kingdom (2005)</td>
<td>na</td>
</tr>
<tr>
<td>Taiwan (2006)</td>
<td>na</td>
</tr>
<tr>
<td>Iceland (2005)</td>
<td>na</td>
</tr>
<tr>
<td>Mexico (2005)</td>
<td>na</td>
</tr>
<tr>
<td>Averages</td>
<td>5.1</td>
</tr>
</tbody>
</table>

* Countries selected on the basis of data from population-wide surveys, purported to be ‘representative’ of the population at large. eGFR classifications using the MDRD abbreviated formula unadjusted or adjusted for population characteristics [for details, see 21, 22, 29, 31–41].

* Averages exclude USA-NHANES; stage 1–2 includes all data; stage 3–4 includes only data where the two stages were separately evaluated.
the USA from NHANES [30]. Indigenous populations, hospitalized patients, nursing home residents or those who have had laboratory measurement of a serum creatinine level by the direction from their physician understandably have much higher estimates of prevalence of CKD [43–45].

It seems clear to us that a population-wide study of CKD prevalence which uses the 2002 KDOQI-CKD formulation in an unmodified fashion and which also uses the standard, re-expressed four-variable MDRD formula for determining eGFR based on single measurements of serum creatinine concentration will greatly overestimate the 'true' prevalence of CKD. We doubt seriously that almost 820,000,000 of the world's 6.2 billion persons have 'true' CKD. Adjustment of eGFR according to geographic ancestry (Black vs. non-Black) in the MDRD equation can also be very problematical in populations where geographic ancestry is very diverse, such as in South America.

Very few international comparisons of the prevalence of CKD and treated ESRD have been conducted. In one such comparison, Hallan et al. [34] found that the prevalence of KDOQI-defined CKD stages 3–4 was very similar in Norway (4.36% in 1995–1997) compared to the USA (5.01% in 1998–1994). The extraordinary observation that emerged was that the treated ESRD incidence in Norway was 106 per million population per year (pmpy) compared to 308 pmpy in the USA and the ratio of stage 3–4 CKD prevalence (pmpy) to treated ESRD incidence (pmpy) ratio in Norway was 416 while it was 163 in the USA, a 2.55-fold difference. These comparisons were made for the Caucasian population only since Blacks were not represented in the Norwegian sample. It was reasonably assumed that access to and indications for initiating RRT and the competing mortality from CVD during the course of CKD were equivalent in the two countries. The large difference in the risk of needing and receiving treatment for ESRD despite an equivalent prevalence of later stages of CKD remains unexplained. Differences in the rates of progression of CKD (higher in the USA) were offered as a potential cause [34]. An important implication from this study is that one cannot easily translate the burden of CKD in the community at large into an anticipated need for ESRD treatment. Indeed, among individuals having CKD stage 1–4, only a tiny percentage will require ESRD treatment in succeeding years [31, 46]. Estimates for the CKD to treated ESRD ‘transition’ rate are about 0.15–0.2% per year of follow-up for stage 3 CKD, at least over 10–25 years. Higher ‘transition’ values are observed for stage 4 CKD. One of us (C.W.) conducted an analysis of the ratio of KDOQI-defined CKD prevalence to treated ESRD incidence in the UK using the NEOERICA estimates and the UK Renal Registry (tables 3, 4) [47]. This ratio rose from 220 to 510 for males in the 45- to 54-year age group compared to the 75- to 84-year age group. The difference was even more striking in females. The same ratio increased from 310 to 1,737 in the 45- to 54-year age group compared to the 75- to 84-year age group. Apparently, at least in the UK, elderly women (75+ years old) with KDOQI-defined CKD have little risk of developing treated ESRD (only 0.6/1,000) (table 4). Such cross-sectional analyses need to be confirmed with longitudinal data in other populations.

The main driving force for rising rates of treated ESRD seen in developing countries, but now abating in more developed nations, is not likely to be the changing burden of stages 1–3 CKD prevailing in the community at large [5, 48]. Rates of progression of established ‘bona-fide’ stage 4 CKD and access to RRT for those with stage 5 CKD are far more important determinants of the overall incidence of treated ESRD. Obviously, these observations have critical importance for public health measures designed to diminish the prevalence of treated ESRD, since they help to define the ‘target’ population for control measures directed at reducing the burden of treated ESRD.

<table>
<thead>
<tr>
<th>Table 3. Stage 3–5 CKD prevalence in UK, 2005a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence of CKD (%) by eGFR (ml/min/1.73 m²)</td>
</tr>
<tr>
<td>30–59</td>
</tr>
<tr>
<td>All genders</td>
</tr>
<tr>
<td>Females only</td>
</tr>
<tr>
<td>Males only</td>
</tr>
</tbody>
</table>

*a Adapted from NEOERICA [for details, see 47].

<table>
<thead>
<tr>
<th>Table 4. Ratio of stage 3–5 CKD prevalence (per million population) to treated ESRD (RRT) incidence (per million population)a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age group</td>
</tr>
<tr>
<td>45–64 years</td>
</tr>
<tr>
<td>55–64 years</td>
</tr>
<tr>
<td>65–74 years</td>
</tr>
<tr>
<td>75–84 years</td>
</tr>
</tbody>
</table>

*a Data abstracted from NEOERICA, 2005, and the UK ESRD Registry [for details, see 47].
What Can Be Done to Improve the Assessment of the Global Burden of Chronic Kidney Disease?

Very clearly, the global burden of CKD is not very well understood, particularly in developing nations, and much more epidemiological research is needed. This review has convinced us that the definitions of disease determine the estimates of the burden of disease, a not unexpected result. As applied to CKD, this predicts that a flawed definition (either too all-encompassing or too restrictive) will lead to inaccurate estimates of true prevalence of disease. The widespread use of the 2002 KDOQI system for diagnosis and staging of individuals with ‘so-called’ CKD has likely led to a significant overestimation of the global burden of true CKD. This problem has been compounded when the MDRD eGFR formula was not adapted to the characteristics of the population. The current KDOQI definitions for CKD stages 1–3 are very much in need of revision if we are to obtain a clearer picture of the true global burden of CKD.

This is not a trivial issue. Hundreds of millions of individuals around the globe may be labeled as having ‘chronic kidney disease’ when in fact they do not. False reassurance that CKD is not present in an individual is an equally daunting issue. Until we have a better understanding of the dynamics of the global burden of true CKD and how individual population characteristics modify this burden, legitimate public health measures to identify and control CKD will be hampered.

As a first approximation of the needed changes, one should focus on stratifying the qualifying levels of eGFR for definition of CKD by age and gender. An absolute threshold of eGFR for defining CKD needs to be abandoned and substituted with a percentile distribution adjusted for age and gender, similar to height for age (and gender) charts used by pediatricians for many decades to track the growth of children. In our opinion, ‘microalbuminuria’ alone should not be regarded as a qualifying criterion for the diagnosis of CKD, but should be relegated to its proper status as a ‘risk factor’ for possible later development of CKD. Risk factors should not be considered as diseases for the purpose of classification. The current stages 1 and 2 KDOQI-CKD need to be collapsed into a single stage, due to inaccuracies in differentiating these stages based on eGFR measurements alone. Finally, geographic and ancestry-specific coefficients for the MDRD formula (or any other formula designed to estimate GFR) should be developed by appropriate comparisons of the results of the estimating formula with true GFR measurements in a group of individuals, of broad age limits, representative of both healthy and diseased (with evidence of chronic kidney damage) individuals in the population as a whole.

Armed with reliable knowledge regarding a priori prevalence of disease, one can then determine the potential effectiveness and cost of any prospectively designed disease control program. Expectations for the effectiveness of screening for CKD (number needed to screen to prevent a single case of ESRD or a single case of premature death due to CVD) can then be analyzed. Control programs directed at prevention of treated ESRD or CVD through early identification of CKD should be both realistic and based on better longitudinal studies of the global prevalence of progressive disease.

References

18 Kestenbaum B, De Zeeuw D, Hillege HL, de Jong PE, Kestenbaum B, Rudser KD, de Boer IH, Per-16 De Zeeuw D, Hillege HL, de Jong PE, Kestenbaum B, Rudser KD, de Boer IH, Per
Editorial Comment
M. El Nahas, Sheffield

The minireview by Glassock and Winearls, in the current issue of Nephron Clinical Practice, highlights major issues relating to the current classification of CKD. Whilst there is no doubt that the KDOQI/KDIGO classification of CKD has contributed considerably to increasing awareness of CKD and its scope, it has also been the subject of some controversy. This minireview raises concerns regarding a number of points relating to the classification and its implications. It questions the validity of a number of assumptions made by the CKD classification. It also expresses concern, shared by many, that the current ‘epidemic’ of CKD reported since the introduction of the CKD classification may be a gross overestimate based on false assumptions such as the inclusion of those with microalbuminuria as suffering from CKD as well as those with age-related reduced kidney function, thus overinflating the number of CKD patients worldwide. Glassock and Winearls critically and wisely appraise the current situation and make timely recommendations. Time may have come for a revision of the current CKD classification. This minireview lays the foundation for such a debate.